KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2016 - 2025)

Pacific Biosciences Of California has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $784.1 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $784.1 million for Q4 2025, down 37.79% from a year ago — trailing twelve months through Dec 2025 was $3.3 billion (down 44.42% YoY), and the annual figure for FY2025 was $784.1 million, down 37.79%.
  • Liabilities and Shareholders Equity for Q4 2025 was $784.1 million at Pacific Biosciences Of California, down from $803.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for PACB hit a ceiling of $2.0 billion in Q4 2021 and a floor of $784.1 million in Q4 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $1.7 billion (2024), compared with a mean of $1.5 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 483.1% in 2021 and later plummeted 48.45% in 2025.
  • Pacific Biosciences Of California's Liabilities and Shareholders Equity stood at $2.0 billion in 2021, then dropped by 11.95% to $1.8 billion in 2022, then decreased by 1.19% to $1.7 billion in 2023, then dropped by 27.81% to $1.3 billion in 2024, then plummeted by 37.79% to $784.1 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $784.1 million (Q4 2025), $803.2 million (Q3 2025), and $825.5 million (Q2 2025) per Business Quant data.